26 studies found for:    aptamer
Show Display Options
Rank Status Study
1 Completed A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: ARC1905
2 Completed
Has Results
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030 plus Lucentis;   Drug: Lucentis
3 Completed ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: ARC1905
4 Completed A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: E10030
5 Completed Phase II/III Study of Anti-VEGF in Neovascular AMD
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: EYE001 anti-VEGF aptamer
6 Completed Safety and Dosing Evaluation of REG1 Anticoagulation System
Condition: Healthy
Intervention: Drug: REG1
7 Completed EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
Condition: Hippel-Lindau Disease
Intervention: Drug: EYE001
8 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
9 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
10 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
11 Completed A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Condition: Age-Related Macular Degeneration
Intervention: Drug: Pegaptanib sodium
12 Terminated A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: Pegaptanib sodium
13 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: bevacizumab  or  aflibercept;   Drug: E10030 sham intravitreal injection
14 Completed Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Condition: Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium (Macugen)
15 Terminated A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: AS1411;   Drug: Cytarabine
16 Completed NOX-E36 First-in-Human (FIH) Study
Conditions: Chronic Inflammatory Diseases;   Type 2 Diabetes Mellitus;   Systemic Lupus Erythematosus
Interventions: Drug: NOX-E36;   Drug: Placebo
17 Completed NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
Condition: Hematopoietic Stem Cell Transplantation
Interventions: Drug: NOX-A12;   Drug: Filgrastim;   Drug: NOX-A12 in combination with Filgrastim
18 Completed NOX-A12 First-in-human (FIH) Study
Condition: Autologous Stem Cell Transplantation
Intervention: Drug: NOX-A12
19 Withdrawn A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
Condition: Von Willebrand Disease
Intervention: Drug: ARC1779
20 Completed ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Conditions: Purpura, Thrombotic Thrombocytopenic;   Von Willebrand Disease Type-2b
Intervention: Drug: ARC1779

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years